BRIEF—Rezo Therapeutics launches with $78 million backing

A new drug discovery company in California has launched with $78 million in a series A financing led by SR One, a16z Bio + Health and Norwest Venture Partners.

Rezo Therapeutics is developing a novel approach to mapping disease networks for precision therapeutics, with technology and personnel coming from the University of California, San Francisco (UCSF).

The scientists who started work on the technology at UCSF, Nevan Krogan and Kevan Shokat, believe the approach will enable them to rapidly pinpoint novel, druggable targets that can be attacked with a range of treatment modalities.

Now co-founders at Rezo, they aim to advance a pipeline of therapies, initially focused in solid tumor oncology, guided by mutation and allele-specific biomarkers.